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                                                  ABSTRACT 
 
Title: A STUDY OF METABOLIC SYNDROME IN PSORIATIC PATIENTS 
Background: Psoriasis is a chronic immune mediated inflammatory disorder of the skin and 
joints. Recent studies have shown increased prevalence of traditional cardiovascular risk 
factors such as diabetes mellitus, hypertension and metabolic syndrome. Thyroid gland 
hormones cause an increase of epidermal growth factor level which has an important role in 
keratinocyte proliferation, which may be involved in psoriasis disease. 
Aims& Objectives::To study the relationship between psoriasis and metabolic syndrome and 
to correlate the same with thyroid profile. 
Materials and Methods: This study was conducted in Chennai Medical College Hospital 
and Research Centre, Irungalur, Trichy. Hundred  psoriatic  patients   in the  age  group  of 
20-80  years in, and 30 controls  were  selected  for  this study. Fasting blood glucose by 
GLUCOSE OXIDASE AND PEROXIDASE method, serum lipid profile by enzymatic 
method and serum thyroid profile by ENZYME LINKED IMMUNOSORBANT ASSAY 
method. 
Results: Our study shows that prevalence of metabolic syndrome in cases of psoriasis to be 
out of 37%, compared to controls among patients with other dermatological conditions to be 
3.3%, (p <0.001) and shows the FT3 (pg/ml) in cases Mean to be 2.117 and in Controls Mean 
was 2.037, Mean difference (0.0803), p value (0.53) .Shows the mean of  FT4 (pg/ml) in 
cases Mean (1.284),  Controls Mean (1.303),and the Mean difference  was (-0.0193), p value 
(0.809) likewise TSH (mIU/ml) in cases Mean to be (3.580), in Controls Mean (2.277), and 
the Mean difference was (1.303), p value (0.001).  
Conclusion: Patients of psoriasis have higher prevalence of metabolic syndrome and 
subclinical hypothyroidism than general population. Therefore identification of metabolic   
syndrome and thyroid profile testing can be done routinely for better management of 
psoriasis. 
Key words: Metabolic Syndrome, Psoriasis, Thyroid hormones, inflammatory 
mediators. 
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                                                   INTRODUCTION 
Psoriasis is chronic an autoimmune inflammatory disease .Which is affecting  
the skin, scalp, nails, and sometimes joints that affects 1-2 % of general population   
across the world. 
This disease is characterized by scaly, erythematous (reddened) patches, 
papules, and plaques which are usually pruritic (itchy) 1. There are five main types of 
psoriasis: plaque, Guttate, inverse, pustular, and erythrodermic. The most common 
form, plaque psoriasis, is commonly seen as red and white hues of scaly patches 
appearing on the top first layer of the epidermis (skin), giving the   skin, a silvery 
white appearance. 
Psoriasis is usually diagnosed based on the appearance of the skin; there are no special 
blood tests or diagnostic procedures.2 Usually a skin biopsy, or scraping, may be 
needed to rule out other disorders and to confirm the diagnosis. Biopsy from the skin 
will show clubbed rete pegs if positive for psoriasis. Another sign of psoriasis is 
Auspitz's sign that when the plaques are scraped, one can see pinpoint bleeding from 
the skin below . 
Psoriasis is their severe form affects quality of life is the affected patients like any 
other chronic illness like hypertension, type 2 diabetes and depression3. 
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National Psoriasis Foundation survey of 426 psoriasis patients, 71 percent reported the 
disease was a significant problem in everyday life 4. It is now thought to be a systemic 
disease with health implications beyond the skin manifestations.5   
The  Metabolic syndrome which is characterized by obesity, hypertension, 
dyslipidemia and impaired glucose tolerance 7.  
The different analysis have suggested that psoriatic patients have an increased risk of 
myocardial infarction, stroke, vascular inflammation and atherosclerotic conditions 
independent of traditional risk factors for cardiovascular disease.6 Correlation between 
psoriasis and Metabolic Syndrome and the effect it has on the patient’s health and on 
the efficacy and safety of treatment options, it is important that patients undergo 
appropriate screening as part of routine medical care 8, 9. 
This disease is a common, chronic relapsing skin disease. Some endocrinological 
disturbances exacerbate the disease. Psoriasis is an early sign of hypothyroidism and 
sometimes associated with more severe form of hypothyroidism 10. 
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                                                       AIM: 
1. To study the relationship between psoriasis and metabolic syndrome in                   
psoriatic patients by performing lipid profile and plasma glucose levels. 
2. To study the correlation of psoriasis with Thyroid dysfunction by estimating FT3, 
FT4 and TSH in psoriatic patients. 
                                      OBJECTIVES 
1) To study the prevalence of metabolic syndrome in different types of Psoriasis. 
2) To study the prevalence of Thyroid dysfunction among Psoriatic patients. 
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                                   REVIEW OF LITERATURE 
1. Farber et al 1977; Identified in childhood psoriasis the familial incidence is greater 
when compared to adult onset psoriasis 11. 
2. Krueger et al 1984; The hyperproliferation of epidermis , terminal differentiation 
are the fundamental abnormalities in psoriatic skin, there is an inflammatory process 
involving cytokines, chemokines, antigen-presenting cells . 
3. Ettehadi et al 1994; The Tumour Necrosis Factor -alpha appears to be a critical 
cytokine in the Psoriasis pathogenesis, where it is crucial for keratinocytes 
hyperproliferation, endothelial cell regulation, and function of memory T cells  
4. Lakka et al in 2002; Systemic inflammation which is correlated with metabolic 
syndrome, with proinflammatory cytokines such as tumor necrosis factor α and C 
reactive protein levels being elevated compared to those without metabolic 
syndrome12. 
5. Feldman et al 2004; Showed the psoriatic severity namely mild psoriasis, 
moderate, and severe based on affected body surface area (BSA) (<3% , 3-10% and 
10%) 13 respectively. 
6. Gordon and Ruderman 2006; Demonstrated that inflammatory mediator levels are 
increased in psoriatic lesions, when compared with normal skin of non psoriatic 
individuals.  
7. Sommer et al in 2006; Showed that an increased frequency of metabolic syndrome 
and it’s components amongst subjects with psoriasis 14. 
18 
 
8. Ludwig et al  in 2007; studies showed Increased frequency of metabolic syndrome 
in psoriasis  leading   in turn to risk of cardiovascular disease and increasing  mortality 
rate15. 
9. Gisondi et al in 2007; Demonstrated that the association would not to be related to 
age, sex or the kind of psoriasis 16.  
10. Sterry et al in 2007; Identified that tobacco addiction, obesity, physical activity, 
depression, poor food habits and psychological stress responsible for the Metabolic 
Syndrome and   increasing risk of coronary artery disease17. 
11. Setty et al in 2007; Found that healthy food could have beneficial effects on 
psoriasis and shows the strong associations among obesity, weight gain, and psoriasis 
18
. 
12. Rakesh et al 2008; Analysis concluded that psoriatic patients self – conscious 
inconvenienced by the shedding of the skin live in a fear of relapse and avoid social 
interactions19. 
13. Gelfand et al in 2009; suggested that psoriasis is linked with an increased 
frequency of adverse outcomes like myocardial infarction, stroke and cardiovascular 
death 20. 
14. Mehta et al in 2009; Identified that, severe psoriasis can be a risk factor for 
atherosclerotic disease 21. 
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15. Abuabara et al in 2010; Identified with severe psoriatic patients die about 5 years 
younger when compared to without psoriatic groups ,  cardiovascular death which is 
the most common cause of excess mortality in these patients 22. 
16. Prey in 2010; There is some dispute, regard to its relationship to the severity and 
duration of the disease 23. 
17. Mebazaa et al in 2010; Found prevalence of metabolic syndrome increased in 
females with psoriasis 24. 
18. Zindancy I et alin 2012; Demonstrated that Metabolic Syndrome which is more 
among women than men owing to higher   BMI and Waist circumference 25. 
19. Shapiro et al in 2012; Authors suggested that the Metabolic Syndrome in 
psoriasis due to chronic presence of systemic inflammation, certain pro inflammatory 
cytokines and immunological mediators 26. 
20. Ozer African et al in 2004; Concluded that the PASI (Psoriasis Area Severity 
Index) scores were higher among psoriatic patients caused by the direct or indirect 
effects of thyroid hormones 27. 
21. Shraddha Madanagobalane et al in 2012; Suggested that Metabolic syndrome is 
more frequent in patients with psoriasis and they also found that no relationship 
between disease severity and presence of metabolic syndrome 28. 
22. Sristi Lakshmi et al in 2014; Concluded that there is no close relation between 
psoriasis and metabolic syndrome in south Indian patients 29. 
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One of the common, chronic disfiguring inflammatory and proliferative condition of 
the skin is psoriasis, both genetic and environmental factors can influence a major 
role. Psoriasis is in duration, periodicity of flares and extent morphological variants 
are common30. 
INCIDENCE AND PREVALENCE: 
In China, psoriasis is essential to affect the population, but the disease is very rare or 
nonexistent in Inuits, Samoans or Latin American Indians. It is very common in East 
than West Africa. Climate also appears to affect psoriasis. 
AGE OF ONSET: 
  Lomholt’s  reported age of onset of Psoriasis in childhood in his study in the Faroe 
Islands. In a US study the average age of onset was 28years, the analysis reported in 
China, the mean age of onset was 36 years.  
SEX EFFECTS:   
Psoriasis equally affects males and females. The variety of analysis indicated that age 
of onset of Psoriasis is younger in females. One Indian survey Sristi Lakshmi et al in 
2014 reported that proportion of metabolic syndrome was significantly higher in 
females than males 29.48,49. 
 ETIOLOGY: 
  GENETIC EPIDEMIOLOGY: 
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Many evidence suggested, psoriasis which has an important genetic component. 
Lomholt’s classic epidemiological study of psoriasis in Foroe Island in 1963 showed 
that Psoriatic prevalence was greater in first and second degree relatives of sufferers. 
ENVIRONMENTAL RISK FACTORS: 
Environmental factors linked to psoriasis for both  the disease initiating process and 
exacerbation of pre-existing disease. 
TRAUMA:   
Physical, chemical, electrical, surgical, inflammatory & infective insults recognised to 
induce lesions of psoriasis called as Koebner’s   phenomenon. 
INFECTION: 
Streptococcal infection is important in chronic plaque psoriasis.  
DRUGS:  
Many reports suggested that, antimalarials drugs, beta blockers , angiotensin–
converting enzyme inhibitors , non steroidal anti inflammatory drugs (NSAIDS), and 
withdrawal of corticosteroids,  these drugs are favorable for the onset  and 
exacerbation of psoriasis   
SUNLIGHT: 
Recent work indicated that severely photosensitive psoriasis is predominantly female, 
distinct from polymorphic light eruption and strongly associated with HLA-CW6, 
family history and early age of onset.  
22 
 
PSYCHOGENIC FACTORS: 
 Several studies suggested that the impact of psoriasis on physical and mental 
components of the quality of life index similar to other major diseases including heart 
disease and arthritis  
SMOKING AND ALCOHOL: 
Both smoking and alcohol have detrimental effect on psoriasis. 
HIV AND AIDS: 
The relation between severe psoriasis, psoriatic arthropathy and HIV infection is 
recognised. 
CARDINAL CHARACTERISTICS OF PSORIATIC LESIONS: 
1. Epidermal hyperproliferation with loss of differentiation,  
2. Dilatation and proliferation of dermal blood vessels,  
3. Accumulation of inflammatory cells. 
FACTORS ALTERED IN PSORIATIC SKIN: 
1. The Growth factors  
 2. The Cytokines 
3. The Inflammatory mediators 
4. Other biological markers. 
 
23 
 
PATHOGENETIC MECHANISMS: 
EPIDERMAL PROLIFERATION: 
              Proliferation of keratinocytes illustrated in psoriasis because of an increase in 
the proliferating cell component in the basal levels of the epidermis, and not due to 
shortened cell cycle time. Multiple growth factors are the mediator of these events 37. 
VASCULAR CHANGES: 
       Epidermal keratinocytes are the primary sources in angiogenic activity and 
dermal capillaries accelerate the inflammatory process through the expression of 
molecules involved in leukocyte homing, stimulated by inflammatory mediators.  
MOLECULAR GENETICS: 
  PSORS 1 is a genetic determinant of the psoriasis, which probably accounts for 
30-50% of the heritability of the disease and has been replicated in all linkage 
studies. PSORS 1 is located within the major histo compatability complex (MHC) 
on chromosome 6p.Guttate psoriasis is strongly PSORS 1 associated, whereas 
palmoplantar pustulosis and late onset (> 50 years of age) psoriasis vulgaris are 
not associated. 
Most of the studies published in western populations with only little information 
about Indians [31]. Chablani et al in 1992 in a study of 67 psoriasis patient from 
western India found association with the A1, B17 and Cw6, but not with B13 
antigens 32. 
Pitchappan et al, in 1989 reported association of HLA Bw57 and DR7 with 
psoriasis vulgaris in south India 33. Rani et al, in 1998 showed that Cw FN 
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X010602 was the main allele that had high frequency in psoriasis patients in 
India38 .Indian studies reported lower familial incidence of the disease 34. Bedi at 
al in 1995 reported positive family history of psoriasis in 14% of their patients 35, 
39
. While Kaur et al in 1997 reported family history in only 2% of their patients 36, 
40
. 
INFLAMMATION AND IMMUNOLOGY: 
Most  commonly the T lymphocytes which play a major role in development of 
plaques of psoriasis.   This includes. 
1. The Early influx of T cells expanding lesions 
2. Strong association with the MHC, particularly HLA –CW6 
3. Ablative action of anti-T cell therapy.2.Increased antigen presentation in 
psoriatic plaques. 
4. Anecdotel of development of psoriasis in syngeneic bone marrow transplant. 
KOEBNER AND REVERSE KOEBNER PHENOMENA: 
       The koebner phenomena usually occurs 7-14 days after injury.  
CLINICAL FEATURES: 
  Acute Guttate attack of psoriasis occurs in childhood. The Most common form of 
psoriasis occurs before fourth decade of life. The dorsal tongue exhibit geographic, 
annular white patches. Nail changes include ‘oil spots’nail pitting, distal 
oncholysis and accumulation of subungual debris [30].Thirty percent or more 
psoriatic patients have inflammatory arthritis, commonly presents as an 
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asymmetric oligoarthritis affecting distal or proximal interphalangeal joints. 
Psoriatic patients appear to be an increased risk for developing obesity, diabetes 
mellitus, hyperlipidemia, hypertension and cardiovascular disease 41, 48, 49 . 
CLINICAL VARIANTS:  
        1. PLAQUE TYPE 
       2. GUTTATE TYPE 
             3. PUSTULAR TYPE   
            4. ERYTHRODERMIC TYPE  
 1. PLAQUE PSORIASIS: 
             It is well   demarcated, erythematous plaques with an adherent, silver to white 
– colored scale. 
AUSPIT’Z SIGN: The pinpoint bleeding on the skin may be seen while the adherent 
scales are removed. 
WORONOFF’S RING: Plaques have surrounding   hypopigmentation called as 
WORONOFF’S RING. 
GUTTATE PSORIASIS 30: 
         It occurs more commonly in young adults, and it presents with multiple 
small, ‘drop shaped ‘erythematous scaly plaques diffusely on the body, most 
frequently on the trunk.  
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PUSTULAR PSORIASIS: 
        It is characterized by superficial pustules .It may be localized on the palms 
and soles like palmoplantar pustulosis or may be generalized. 
ERYTHRODERMIC VARIANT: 
       It is characterized by diffuse erythroderma with fine scaling. 
DIAGNOSIS: 
               The psoriatic diagnosis is usually based on clinical findings. Evidence are 
supporting the diagnosis includes typical morphology and anatomic locations of the 
skin lesions, presence of nail lesions or arthritis and a positive family history of 
psoriasis .Skin biopsy useful in atypical cases. 
                  PSORIASIS WITH METABOILC SYNDROME: 
            Variety of surveys have reported that elevated level of serum immunological 
markers, like Interleukin -6, Interleukin-2 receptor, TNF-alpha and ICAM-1, in 
psoriasis being a systemic immunologic disorder 54,55,57, .  
                                     METABOLIC SYNDROME: 
 The other names are Insulin Resistance Syndrome, Syndrome X, which consists of 
metabolic abnormalities with increased risk of coronary heart disease and diabetes 
mellitus. 
  NCEP: ATP 2001 CRITEARIA FOR METABOLIC SYNDROME:    
1. Fasting Plasma glucose: is ≥ 100mg/dl or in specific medication or previously 
diagnosed   Type 2 diabetes mellitus. 
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2. Hypertension: Blood Pressure is ≥ 130 mmHg of systolic or ≥ 85 mmHg of 
diastolic or in specific medication. 
3. Hypertriglyceridemia: Triglyceride level is   ≥ 150 mg/dl or with specific 
medication 
4. Low HDL –c: is <40 mg/dl in males, <50mg/dl in females or with specific 
medication. 
5. Obesity mainly central:  Waist Circumference is > 102cm in males, >88 cm in 
Females. 
EPIDEMIOLOGY [42]: Worldwide the metabolic syndrome is in Native Americans, 
60% of females age 45-49 & 45% of male’s age 45-49 years. The rising prevalence in 
children and severity of obesity is initiating features of the metabolic syndrome in a 
younger ages. 
RISK FACTORS: 
OVERWEIGHT/OBESITY: 
Body mass is positively related to fasting triglycerides concentrations, plasma 
cholesterol and blood pressure, inversely related to HDL –cholesterol. Waist 
circumference is a significantly better index of insulin resistance than Waist / 
hip ratio or BMI. A cut of value for waist circumference of < 100cm rules out 
insulin resistance in both male and female with optimal sensitivity and 
specificity. Body mass index of > 30 Kg/m2 is considered as “obesity” and it 
plays a major role in atherosclerotic progression 43, 44. 
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 STRESS:                       
Prolonged  stress which is an underlying  cause of metabolic syndrome  by the 
hormonal  balance  of the hypothalamic – pituitary – adrenal  axis.( HPA-
AXIS).A   dysfunctional HPA-axis causes high cortisol  levels  , which causes 
rising glucose and insulin levels, which  in turn results insulin mediated effects 
on adipose tissue, promoting visceral obesity , insulin resistance , dyslipidemia 
and hypertension , with direct effects on bone , causing “   low turnover “ 
osteoporosis 45. 
SEDENTARY LIFESTYLE: 
MS components are associated with a sedentary lifestyle, included increased plasma 
glucose, high blood pressure increased triglyceride, reduced HDL cholesterol and 
increased adipose tissue. 
AGING: 
In US study 44 percentages of MS affected people age were older than 50 years. In 
this study an increased percentage of women have the MS than men over age 50 42. 
TYPE 2 DIABETES MELLITUS 42: 
Base on both the National Cholesterol Education Programme and International 
Diabetes Foundation definitions of the Metabolic Syndrome Type 2 diabetes mellitus 
is included. In MS the risk of  type 2 diabetes mellitus is increased three to five fold. 
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HYPERINSULINEMIA AND INSULIN RESISTANCE: 
    Insulin resistance refers to the decreased rate of glucose uptake mediated by insulin 
.It was shown to be accompanied by increased levels of insulin and undesirable 
changes in cardiovascular risk factors like  high levels of triglycerides , decreased 
HDL cholesterol , and development of hypertension. In addition adipose tissue is now 
recognised to be a source of a number of inflammatory cytokines (interleukin -6), 
tumour necrosis factor α (TNF- α), and growth factors (Heparin binding epidermal 
growth factor (HB-EGF) hormone like substances (leptin, adiponectin, resistin) 46. 
 HYPERTENSION: 
       Cardiovascular risk increases both with increasing systolic and diastolic pressure 
cholesterol is a continuous variable like blood pressure and there is no comprehensible 
cut –off value doubles the risk of CHD at any given concentration of cholesterol. 
   HYPER TRIGLYCERIDEMIA: 
      Hypertriglyceridemia state promotes the oxidative and proinflammatory milieu 
enhancing expression of adhesion molecule formation of foam cell and intoxication of 
smooth muscle cell. Following hydrolysis, chylomicrons which are exogenously 
derived, VLDL cholesterol secreted   endogenously enriched remnant by products 
enters the endothelial space. Hypertriglyceridemia increases reverse cholesterol 
transport   that 10% lowering  of TGL concentration decreases  the risk of CHD by 
23% 47,56 . 
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CHD (CORONARY HEART DISEASE): 
  The Metabolic Syndrome components are increased risk for coronary heart disease 50, 
51
. 
LIPODYSTROPHY:  
 Both congenital and acquired lipodystrophy can give rise to insulin resistance and 
other components of  the MS. 
PATHOPHYSIOLOGY OF METABOLIC SYNDROME: 
            Which is the most common for there a development of visceral  fat and which 
the  adipocytes that can increases the plasma  TNF alpha level and  alter  the level  of 
adiponectin , resistin .Chronic inflammation contributes to an increased risk of 
hypertension, atherosclerosis and diabetes . 
CLINICAL FEATURES: 
SYMPTOMS AND SIGNS: 
         The metabolic syndrome is typically not associated with symptoms. On physical 
examination presence of elevated blood pressure and expanded waist circumference 
and other biochemical abnormalities including increased triglycerides, decreases HDL 
cholesterol and increased fasting blood sugar.  
OTHER ASSOCIATED CONDITIONS: 
       Those alterations include increased level of apo B , apo C-III,  Plasminogen  
activator I, Fibrinogen level , Homocysteine level , Asymmetric  level of 
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dimethylarginine, increased white blood cell count, increased level of Inflammatory 
Cytokines, raised C-Reactive Protein level, Microalbuminuria , Hyperuricemia, Non-
Alcoholic Fatty Liver Disease , Poly Cystic Ovarian Disease  and Obstructive Sleep 
Apnea 52,53 . 
DIAGNOSIS: 
     Blood pressure and waist circumference measurements provide information 
necessary for the diagnosis. 
LABORATORY TESTS: 
          Fasting lipid profile and blood glucose are needed to determine the metabolic 
syndrome. Measurements of other biomarkers associate with insulin resistance, 
included, Plasma fibrinogen, hsC- Reactive Protein, urinary microalbumin, serum uric 
acid and liver function tests. 
THYROID DYSFUNCTION IN PSORIASIS: 
Psoriasis can be exacerbated by endocrinological disturbances especially due to 
thyroid hormones. The thyroid hormones T3 and T4 increase in leads to epidermal 
hyperplasia 27. Antithyroid hormonal drugs like propylthiouracil, anti thyroid 
preparation, elevated number of cytotoxic T cells, suppressor cells, and lowered level 
of lymphocytes in psoriatic plaque type. Receptors of Triiodothyronine can play a 
major role in the keratin synthesis, an anti thyroid drug like Propylthiouracil, which 
may affects the synthetic process of keratin by binding  with Triiodothyronine  nuclear 
receptors. 
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Thyroid hormones have hyper proliferative effect on the skin by EGF. The skin is 
most  important tissue for thyroid hormones like Triiodothyronine and 
Tetraiodothyronine and these hormones can increase the level of EGF (Epidermal 
growth factor) that accelerate the proliferation of epidermis. When thyroid function is 
low, prolactin increases with psoriasis .Prolactin increases cell division and sebum 
formation whereas darkness and stress increase it .This may be the connection 
between sunlight and the alleviation of psoriasis27. 
To our knowledge there are few studies in India on Psoriasis related with Metabolic 
Syndrome and thyroid dysfunction. Hence it is proposed to study the recent 
prevalence of metabolic syndrome in psoriatic patients. It is also proposed to find out 
the association of thyroid dysfunction in psoriatic Patients. 
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                               MATERIALS AND METHODS 
STUDY DESIGN               : Case and control study 
PLACE OF STUDY          :  Department of Bio Chemistry 
                    The CMCH & RC (Chennai Medical College Hospital and Research 
Centre),     Trichy. 
PERIOD OF STUDY: JANUARY 2014-FEBRAUARY 2015                                     
SAMPLE SIZE                :  100 Cases and 30 Controls. 
                   (Cases- psoriatic patients) (Controls – non psoriatic patients) 
 AGE                                 :     20-80 years  
 SEX                                  :     Both females and males. 
 GEOGRAPHICAL DISTRIBUTION:  Both urban and rural areas.  
 ETHICAL CONSIDERATIONS 
       The necessary approval was obtained to conduct the study from the 
CMCH & RC, ethical committee, Trichy. Patients were given an explanation 
about the purpose of the study and informed written consent was obtained, 
confidentiality about their results was assured. Their participation was 
optional. 
SELECTION OF CASES AND CONTROLS: 
     Hundred  psoriatic  patients   in the  age  group  of 20-80  years in CMCH & RC, 
Irungalur , Trichy, and 30 non psoriatic patients other than psoriasis who  were all 
attending  in  Dermatology department ,in the same age  group as control  were  
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selected  for  the study. All the patients were included as cases evaluated and 
diagnosed as psoriasis on the basis of history, clinical findings and skin   biopsy. 
 CASES:  
 Inclusion Criteria:   
                                    1. Patients with psoriasis (age groups 20-80 years)    
2. psoriatic   Patients with  metabolic syndrome                                                                                             
                                    3. Psoriatic arthritic patients 
      Exclusion Criteria:   1. Psoriatic patients < 20 years.  
                                             2. Psoriatic patients with associated chronic autoimmune 
disorders like Systemic Lupus Erythematous, Rheumatoid arthritis, Asthma. 
CONTROLS: 
  Inclusion   Criteria:  Patients attending the Dermatology Department suffering from 
skin diseases other than psoriasis. 
  Exclusion Criteria: Non psoriatic patients with chronic autoimmune disorders like 
Systemic Lupus Erythematous, Rheumatoid arthritis, Asthma. 
  STUDY PROTOCOL: 
Informed consent obtaining from the subjects who were all included for study and 
patients were subjected to history taking and the clinical examination. 
 DETAILED HISTORY: 
      A detailed history was elicited for  
• Duration of the disease  
• Severity and Symptoms of disorder 
• Arthritic pain 
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• Smoking habits, consumption of alcohol details and diet habits . 
• Co-morbid diseases and concomitant drugs intake. 
• Native treatment. 
• Treatment before hospitalization. 
CLINICAL EXAMINATION:  
A thorough physical examination was done to look for local and systemic features. 
Psoriatic involvement was assessed using Body Surface Area (BSA) [30].  
The national psoriasis foundation defines mild, moderate and severe psoriasis 
 MILD                           :   If affected upto 3 percentage of the body, especially in 
isolated patches on the elbows, hands, knees feet and scalp. This can be controlled by 
topical therapy. 
 MODERATE   TYPE       :    In this type the body’s surface affected from 
3percentage – 10percentage, especially on the scalp, arms, legs, torso and other areas. 
Treatments for this type are topical agents, phototherapy, systemic medications may 
be given. 
SEVERE PSORIASIS             :    It affects   the body surface more than 10%. It may 
be extensive with plaques, pustules or erythroderma. Treatment for this type are 
Phototherapy, systemic medications, or a combination of these, with or without a 
topical agent , are necessary to achieve adequate results. 
ANTHROPOMETRIC MEASUREMENTS: 
Height in cm, weight in kg, waist circumference in cm and blood pressure in mmHg 
measurements were done. 
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1. Based on weight and height calculations the Body Mass Index (BMI) was 
determined by  using the following equation 
                     BMI = Weight in Kilogram / height in meters Square    
According to rule of India, a BMI from 23 to 24.9 is overweight, a Body Mass Index 
is above or equal to 25 is moderate obesity and a Body Mass Index is above or equal 
to 30 in severe type of obesity. 
2. Measurement of waist circumference by the measuring tape which placed at the 
level of the iliac crest snugly around the abdomen.  
3. More than ninety cm waist circumference in men and above 80 cm for women 
was   considered as obesity.   
4. The average of two measurements of blood pressure was recorded in right arm  
and was taken in the sitting posture  
5. INVESTIGATIONS: 
1. Complete Blood Count 
2. Fasting   blood glucose 
3. Fasting plasma lipid (TC, TGL, LDL-c, HDL-c) 
4.  Serum Thyroid profile. 
5. LFT (S. AST,ALT,GGT, Bilirubin  levels were also done) 
COLLECTION OF SPECIMENS 
     Informed consent was obtained for each patient and control groups prior to 
the study. 5ml of venous blood samples were collected in clot activator 
coated polypropylene tubes by venue puncture under strict aseptic 
precaution as soon as the subjects got admitted as per the inclusion 
38 
 
criteria. Serum was separated  by centrifugation for 10 minutes at 3500 
rpm. 8-12 hours fasting samples were collected from all subjects during 
their hospital stay and analysis of total cholesterol, triacylglycerol and 
high density lipoprotein were done.  
SAMPLE STORAGE: 
The specimens were freezed at -20°C for storage until analysis. 
The separated serum was analysed for the following tests: 
1. Fasting Blood Glucose 
2. 2 . Serum lipid profile  
i. Serum  Total Cholesterol 
ii. Serum  Triglycerides 
iii. Serum  VLDL-c 
iv. Serum  LDL–c 
v. Serum   HDL–c 
3. Thyroid profile 
i. Free Triiodothyronine (T3) 
ii. Free  Thyroxine ( T4) 
iii. Thyroid Stimulating Hormone (TSH ) 
iv.  
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QUANTITATIVE ESTIMATION OF FASTING BLOOD GLUCOSE: 
METHODOLOGY:   
GLUCOSE OXIDASE – PEROXIDASE METHOD (END POINT METHOD) 
PRINCIPLE: 
In serum /plasma glucose is oxidized by glucose oxidase (GOD) enzyme and to 
produce gluconic acid with the liberation of hydrogen peroxide then it is converted to 
water and nascent oxygen due to peroxidase (POD) enzyme. 
An oxygen acceptor 4- Aminoantipyrine, which takes up the oxygen and together with 
phenol forms a chromogen (pink colored) then it, can be measured at 505 nm. 
Glucose + o2 (nascent oxygen) + H2O              GOD                      Gluconic acid + H2O2 
H2O2   + phenol + 4-Aminoantipyrine           POD         quinoneimine complex (Red )+ 
H2O 
 GLUCOSE REAGENTS: 
1. Phosphate buffer (Ph 7.5)       : 0.1 mol/L 
2. 4-Aminoantipyrine                  : 5.0 mmol/L 
3. Peroxidase                               :  >1.5 KU/L 
4. Glucose Oxidase                    : >15 KU/L 
5. Phenol                                   :  5.0 mmol/L 
              Glucose Standard (concentration: 100 mg /dl) 
ASSAY PROCEDURE: (FULLY AUTOMATED ANALYZER) 
 Pipette into test tubes and labelled them as Blank (B), Standard (S) and (T) as 
follows: 
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Reaction temperature at 37◦C. 
Mixed well then the absorbance of Standard (S) and Test (T) against 
Blank (B) read at 505 nm or with green filter (500- 540 nm) . 
CALCULATION OF RESULTS 
                                 Glucose conc (mg/dl) =      ∆ Abs for Test    × 100 
                                                                             ∆ Abs for Standard 
    Storage: 
The reagents were stored at 2-8◦c. 
    Reference value: 
       FBS: 70- 100 mille gram/dl 
       PPBS : < 140 mille gram /dl 
                                            
                                                    
 
 
 
  S.NO   REAGENT   BLANK  STANDARD TEST 
1.    reagents of GLUCOSE  1.0 ml 1.0 ml 1.0 ml 
     2. GLUCOSE Std     _ 10 µl   _ 
     3. SPECIMEN      _     _  10 µl 
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                                                    LIPID PROFILE  
                   QUANTITATIVE ESTIMATION OF SERUM  
                              TOTAL CHOLESTEROL      
         METHODOLOGY: 
                         Cholesterol oxidase / peroxidase 
       PRINCIPLE: 
               Cholesterol esters are hydrolyzed to produce cholesterol. Then, free 
cholesterol takes part in two coupled reactions that permit to measure 
cholesterol photometrically. 
          The reaction sequence is as follows: 
c- ester + H2O                        Cholesterase                  Cholesterol  + FA 
                CHOD            
  Cholesterol + ½ O2 + H2O                   Cholestenone   + hydrogen peroxide
 
            Peroxidase 
2H2O2 + 4- AMAT     + Phenol                     chromogen (Quinoneimine)  
+4H2O 
 
  Cholesterol Reagent: 
               Pipes                                : 35 mmol / liter 
              Sodium cholate                 : o.5 mmol / liter 
              Phenol                               : 28mmol/ liter 
              Cholesterol esterase          :  > 0.2 Units/ mille liter 
              Cholesterol oxidase        :    >0.1U/mille liter 
               POD                                :   more than 0.8U/mille liter 
               4-  AMAT                      :    0.5mmol/liter 
               pH                                  :   7.0 
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 Std (5ml): TC 200mg/dl 
  The reagents were stored at 2ºC-8ºC 
PREPARATION OF WORKING SOLUTION: 
           The reagents are allowed to attain room temperature.   
PROCEDURE: 
The sample and working solution are brought to room temperature prior to use. 3 test 
tubes named as blank (B), Standard (S), Test (T). 1 ml of working reagent added in 3 
test tubes then 10µL of sample was added in‘T’ and 10µL of standard was added in 
‘S’. After mixing  then incubated in room temperature for 10 minutes. 
 
 
 
 
     
 
CALCULATIONS: 
Sample absorbance       × 200 = Sample concentration (mg/dl)      
Standard absorbance 
           LINEARITY:  
        This method is linear upto 1000mg/dl. 
REFERENCE VALUES: 
        Serum   TC :( mg/dl) 
            Desirable value              :  up to 200  
            Borderline High value:  200 - 239  
            High   value                   :   > 240  
 Blank Standard Test 
Distilled water    10µL     --  -- 
 Reagent 1mL   1mL  1ml 
Standard  --   10µL  -- 
Sample  --    -- 10µL 
43 
 
                   QUANTITATIVE ESTIMATION OF SERUM TRIGLYCERIDES      
    METHODOLOGY: 
                       Glycerol-3- phosphate oxidase (GPO) 
  PRINCIPLE OF THE METHOD: 
       The estimation of triglycerides by the enzyme of lipoprotein lipase. 
Quinoneimine is an Indicator which is generated by hydrogen peroxide under 
the catalytic action of peroxidase from 4-aminoantipyrine and 4- Chlorophenol. 
  The reaction sequence: 
             Lipoprotein lipase 
     Triglycerides                        Glycerol + FA 
                                                          GK 
     Glycerol + Adenosinetriphosphate                    Glycerol -3-phosphate + ADP 
                    GPO    
     Glycerol -3-phosphate    + O2                     DHAP + Hydrogen peroxide     
        Peroxidase       
     2H2O2 + AMAT  + 4- Chlorophenol                  Quinoeimine + HCl + H2O               
REAGENTS: 
              4-chlorophenol                               :  4 mille mol / Liter 
              ATP                                                :  2 mmol / Liter 
              Mg2+                                               : 15mmol/Liter 
              Glycerolkinase                                :   ≥0.4 kU/ Liter 
               Lipoprotein lipase                           :  ≥ 2 kU/ Liter 
               Peroxidase                                        : ≥ 2 kU/Liter 
                          4-Aminoantipyrine                            : 0.5mmol/l 
              Glycerol -3- phosphate – oxidase     : ≥0.5 kU /L 
               Good’s buffer pH        7.2                 :50 mmol / l 
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            Standard:  Triglycerides 200mg/dl 
  The reagents were stored at 2ºC-8ºC 
PREPARATION OF WORKING SOLUTION: 
           The reagents are allowed to attain room temperature.   
PROCEDURE: 
       The sample and the working solution were brought to room temperature 
prior to use. 3 test tubes labeled like B, S, T. working reagent 1 ml added in all 
3 tubes.  10micro Liter of sample was added in ‘T’ tube and standard 10µL was 
added in ‘S’tube. After it mixed and incubated the tubes at room temperature 
for 10 minutes. 
 Blank Standard Test 
Distilled 
water 
10µl  --  -- 
Reagent 1ml 1ml  1ml 
Standard -- 10µl  -- 
Sample -- -- 10µl 
  
 
 
CALCULATIONS: 
 Sample absorbance       × 200 = Sample concentration (mg/dl)            
Standard absorbance 
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To correct for free glycerol, subtract 10mg/dl from the triglycerides value calculated 
above. 
LINEARITY:  
      This method is to determine triglyceride concentration within a measuring 
range from 2-1000mg/dl. 
REFERENCE VALUES: 
           Serum TGL: (mille gram/dl) 
            Normal   :        < 150  
            High        :        150 – 199 
            Hypertriglyceridemia: 200-499 
            Very High                : > 499  
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                       QUANTITATIVE ESTIMATION OF SERUM  
                 LOW DENSITY LIPOPROTEIN CHOLESTEROL 
METHODOLOGY: 
                       Direct enzymatic method 
PRINCIPLE OF THE METHOD: 
                  LDL is selectively protected while non-LDL-lipoprotein are 
processed by enzyme, then LDL is released and LDL-cholesterol determined in 
a color producing  due to enzymatic reaction. 
       Reaction sequence: 
1. Low Density Lipoprotein +  1.reagnt                          Protected LDL 
                        CHE &CHO 
 Chylomicrons , HDL, VLDL,                             Cholestenone +hydrogen 
peroxide
   
               
Catalase 
 H2O2                                         H2O     
2. Protected LDL + 2. reagnt                               LDL 
          CHE &CHO 
 LDL-c                                      Cholestenone + H2O2 
       
POD
 
 H2O2 + 4- AMAT + H-DAOS                          Color   
          REAGENTS: 
Reagent 1: 
              Cholesterol esterase                                 :  ≥2.5 kU/L 
              Cholesterol oxidase                                 :  ≥ 2.5 k UNITS/L 
               (H-DAOS)                                                  :   0.5mmol/Liter  
              Buffer’s pH 6.8                                   :  20 mille mol / Liter 
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              Catalase                                                       : ≥500 kU/ Liter 
    
               pH of Good’s buffer :7.0                          :25 mille mol / Liter 
                Peroxidase                                               : ≥15 kU/ Liter 
               4-Aminoantipyrine                                   : 3.4mmol/ Liter 
  Calibrator: LDL- Cholesterol 132 mg/dL 
       The reagents were   stored at 2ºC-8ºC 
  PREPARATION OF WORKING SOLUTION: 
           The reagents are allowed to attain room temperature.  
        PROCEDURE: 
       The sample and the working solution were brought to room temperature 
prior to use. Three test tubes named them as B, C, T. 280 µL of working 
reagent 1 added in all 3 tubes. 3.0µL of sample added in ‘T’ tube and 3.0 µL of 
calibrator added to ‘C’ tube.  After mixed and tubes were incubated at room 
temperature for 5 minutes. Read the absorbance A1, then 70 µL of working 
reagent 2 is added to 3 test tubes. It mixed and incubated the tubes for 5 
minutes at room temperature. Read the absorbance A2. 
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Mixed well and incubated 5 min, in 37◦C, read absorbed (A2). 
 ∆A = [(A2 - A1) S or C ] -   [(A2-A1)B] 
CALCULATIONS: 
  ∆A Sample     × conc .calib = Sample concentration(mg/dl)     
 ∆A calibrator  
LINEARITY:  
        This method is to determine LDL-C concentration within a measuring 
range from 1- 400mg/dl. 
REFERENCE VALUES: Serum LDL-c: (mg/dl) 
                       Optimal                    : < 100  
                       Near/above optimal: 100-129 
            Borderline High       : 130- 159  
            High                          : 160- 189 
            Very high                    : >189                
 BLA NK  
(µl) 
CALIBRATOR      
(µl) 
TEST 
(µl) 
 CALIBRATOR        _       3.0   - 
SAMPLE        -         -       3.0 
DISTILLED 
WATER 
      3.0       _  
REAGENT 1      280     280     280 
Mix ,incubate in 37◦C  for 5min,, read  the absorbance (A1), then 
add:   
Reag: 2     70  70  70  
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               QUANTITATIVE ESTIMATION OF SERUM  
    HIGH DENSITY LIPOPROTEIN CHOLESTEROL 
METHODOLOGY: 
                       Direct enzymatic method 
PRINCIPLE OF THE METHOD: 
                     Human lipoproteins are used to form antigen-antibody complexes 
with chylomicrons, VLDL and LDL and that only HDL-c is determined by an 
enzymatic measurement of cholest. 
The reaction sequence is as   follows: 
 
                           Anti-human  
                      β – Lipoprotein antibodies 
LDL,VLDL,  Chylomicrons                                              Antigen – antibody 
complexes +HDL  
      CHE &Oxidase 
HDL –c + H2O +O2                            Cholest-4-en-3-one + Fatty acid +   
                                                                    H2O2       
          POD 
H2O2  + F- DAOS + 4- Aminoantipyrine                         Blue colored Complex +  H2O       
       Reagent 1: 
              The Ascorbate oxidase                                  :   2, 250 Units / Liter 
             The Anti-human β - lipoprotein 
                Peroxidase                                              : 2, 000 U/L 
               4-Aminoantipyrine                                 : 0.75mmol/l 
                Buffer’s pH        7.0                       :  25 mmol / l 
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   Reagent 2: 
                Buffer’s  pH        7.0                       :   30 mille mol / liter 
               CHE                                                 : 4000 Units /Liter 
               CHO                                                 : 20000Units/Liter 
               (F-DAOS)                                        :0.8mmol/Liter 
 Calibrator:  HDL-Cholesterol     : 50.6 mg/dl 
The reagents were stored at 2ºC-8ºC 
PREPARATION OF WORKING SOLUTION: 
           The reagents were allowed to attain room temperature.   
PROCEDURE: 
       The sample and the working solution were brought to room      temperature 
prior to use. Three Test Tubes named as B, C, T. 240 µl of working reagent 1 is 
added to 3 test tubes. 2.4µl of sample was added to test tube labeled ‘T’ and 2.4 
µl of calibrator is added to test tube labeled ‘C’. After mixing tubes were 
incubated 5 minutes in room temperature then read absorbance A1, then 60 µl 
of working reagent 2 was added to 3 tubes. After mixing incubated the tubes 5 
minutes in room temperature then read the absorbance A2.  
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 BLANK 
µl 
CALIBRATOR 
µl 
TEST 
µl 
 CALIBRATOR        _       2.4   - 
SAMPLE        -       - 2.4 
DISTILLED 
WATER 
      2.4       _  
REAGENT 1      240     240 240 
 Mix ,incubate 5min, in  37◦C  then read  absorbance (A1), and 
add:   
REAG: 2     60  60  60  
 ∆A = ( A2 - A1) sample or calibrator. 
CALCULATIONS: 
∆A Sample       ×   conc. Calib =  Sample concentration (mg/dl)     
 ∆A Calibrator  
LINEARITY:  
        This method is to estimate HDL-c concentration within a range of 1-
180mg/deci liter. 
REFERENCE VALUES: 
        Serum HDL-C: Males – 30-60 mg/dl 
       Females – 35-75 mg/dl 
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                     ESTIMATION OF THYROID PROFILE 58: 
                          ESTIMATION OF FT3 (FREE T3) 
METHODOLOGY: 
                        THE ELISA METHOD 
PRINCIPLE: 
     Based on the competitive binding between FT3 in a test specimen and T3 –
Peroxidase conjugate in a limited number of binding sites on the well coated with anti 
–T3 (Sheep) . The amount of T3 –Peroxidase conjugate bound to the well which is 
inversely proportional to the FT3concentration in the specimen. 
    Then the specimen was incubated and T3 –Peroxidase conjugate unbound enzyme 
conjugate is removed in the equilibrium state by washing procedure. Then TMB 
/Substrate solution added after that  a blue color develops. The intensity of this blue 
color , then  changes to yellow after stopping the reaction , this color is inversely 
proportional to the FT3 amount in the specimen. 
  Calibrator’s absorbance and specimen is estimated by using ELISA microplate 
readers or automated ELISA systems (eg. HUMAN’S Huma - Reader or ELISYS 
line) . Specimen’s concentration is extrapolated from a dose response curve generated 
by utilising serum calibrators of known concentration of antigen.   
 KIT COMPONENTS: 
1. STRIPS  
           8 - Well strips, coated by anti –T3 sheep) 
2. CALIBRATORS: ( 6 C , 2 ml per cal) ready for use, in human serum 
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     FT3  CONCNTRATION      Pg/ml 
       Calibrator  1     O (A) 
        Calibrator  2     1 (B ) 
         Calibrator  3     3 (C) 
        Calibrator  4    5 (D) 
         Calibrator  5    8 (E) 
         Calibrator  6    16 (F) 
 
3. ENZYME – ANTIGEN CONJUGATE: (13 ml) 
     Ready for use , coloured red T3 – HRP Conjugate in a protein stabilising 
matrix. -  1%. 
4. WASH SOLUTION : (20 ml) 
    Concentrated of ca.1000ml  
   Buffered saline.  -   250 mmol/l 
5. SUBSTRATE :(in 14ml)  
     3, 3’, 5,5’, (TMB) –   0.5 g/l 
     Buffer (Sodium acetate)  -   0.05mol/l 
     Urea H2O2    -                   0.03% 
6. STOP soln :  ( in 7.5ml) 
    H2SO4                              -0.5 mol/l 
Total concentration  of  preservative < 0.04%. 
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  Stability of the reagents are able up to the expiry  dates on the labels when stored in 
2-8◦ C . Opened reagents can be used within 60 days. 
           MICROPLATE: 
          An aluminium bag sealed the microplate with a desiccant. 
     PREPARATION OF REAGNT:  
• All the reagents brought to room temperature (15-25◦C) before use. 
• Reagents always be stored about s 2- 8◦ C. 
• WASH solution (WS) : 
•  Turbidity, which may appear in the concentrate , will dissolve on dilution. 
• WS diluted with 1000 ml of fresh, deionised water then rinse vial several times. 
• Stability in 15-25◦C  up to 60 days 
TESTING SAMPLE: 
• The Serum  
• Storage of specimens at 2-8◦C up to 5 days if  up to 30 days stored at -20◦C. 
PROCEDURE: 
            1st STEP            WELL (MICROLITER) 
    A1…..D2 
      CAL 
       E2 
   SPECIMEN 
    CAL –A-F; (duplicate)           50          _ 
 SPECIMENS, CONTROLS; 
(duplicate) 
            _         50 
  CONJUGATE           100         100 
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Gently rock and cover the MIC by strip 
Incubate  at 20- 25◦C upto 60 min 
Wash - 3 times  
                WASH          300    300 
               2nd STEP  
              SUBSTRATE          100     100 
No shaking  MIC after SUB addition 
 
Incubate upto 15 min about 
20…25◦C  
 
             STOP          50    50 
  Then  mixed  
 
Measurement of the absorbance as early as possible at 450nm or within 
30min, after reaction termination, reference wavelength using a of 630- 
690nm. 
VALIDATION OF THE TEST: 
      The calibration of highest absorbance :CAL- A ≥ 1.3. 
CALCULATION: 
       The measured absorbance Plotted against the calibrator in a lin –lin 
graph. The Appropriate of plotted measuring points resulted in a 
calibration curve , from the analyte concentration in the sample can be 
determined. 
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REFERENCE VALUE: 
                 
 
 
                        
 
 
       
 
                       
 
 
 
                       
 
 
 
 
 
 
                ADULT      
PREGNANT 
                MEAN 2.8picogram/ml       3.0 pg / ml 
 STANDARD DEVIATION (S.D)   0.7  pg /ml       0.6 pg /ml 
    EXPECTED RANGE (≥2 S.D )  1.4-4.2pg /ml      1.8-4.2pg/ml 
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                               ESTIMATION OF FT4 (FREE T4) 
 METHODOLOGY: 
                       THE ELISA METHOD 
PRINCIPLE: 
     ELISA is used the competitive binding between FT4 in a test specimen and T4 –
Peroxidase conjugation for the limited number of binding sites on the anti –T4( 
Sheep) coated well. The amount of conjugation of T4 –Peroxidase  which is bound to 
the well is inversely proportional to the FT4 concentration in the specimen. 
Then specimen incubated and T4 –Peroxidase conjugate unbound enzyme conjugate 
which is removed in the equilibrium state by washing procedure. TMB /Substrate 
solution is added then a blue color develops. The intensity of this blue color, which 
changes to yellow after the reaction stopped, this blue color is inversely proportional 
to the FT4 amount in the specimen. 
Calibrators absorbance and specimen which is determined by using of ELISA 
microplate readers or automated systems of ELISA (for eg. HUMAN’S Huma - 
Reader or ELISYS line). Concentration of specimen is extrapolated from the dose 
response curve generated by utilising known antigen concentrations of serum 
calibrators 
  
       KIT: 
  MC STRIPS  
           8 - Well  strips , coated by anti –T4sheep) 
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CALIBRATORS: ( 6 cal  ,  2 ml/ cal) ready for use, in human serum 
     FT4 CONCNTRATION      ng/ml 
       Calibrator  1     0 ( A) 
        Calibrator  2     0.40 (B) 
         Calibrator  3     1.25 (C) 
        Calibrator  4    2.10 (D) 
         Calibrator  5    5.00 (E) 
         Calibrator  6    7.40 (F) 
 
ENZYME – ANTIGEN CONJUGATE: (13 ml) 
     Ready  for use, coloured green T4 – HRP Conjugate in a protein stabilising 
matrix. -  1%. 
WASH SOLUTION : (20 ml) 
       Concentrated of ca.1000ml  
   Buffered saline.  -   250 mmol/l 
SUBSTRATE REAGENT :(14ml)  
         3, 3’, 5,5’, (TMB) –   0.5 g/l 
     Buffer (Sodium acetate)  -   0.05mol/l 
     Urea H2O2    -                   0.03% 
STOP soln :  ( in 7.5ml) 
    H2SO4                              -0.5 mol/l 
 
PRESERVATIVES: Total concentration < 0.04%. 
59 
 
The reagents stability are able to stated up to expiry dates on the labels and stored at 
2-8◦C . 
Opened reagents have to be stored at 2- 8◦ C can be used up to 60 days. 
 MICROPLATE: 
           An aluminium bag Sealed with a desiccant. 
PREPARATION OF    REAGENT:  
• Bring all reagents to room temperature (15-25◦C ) before use. 
• Reagents not in uses should always be stored at 2- 8◦ C. 
WORKING WASH SOLUTION: 
• Turbidity, which is Faint and may appear in the concentrate, completely 
dissolve on dilution. 
• Dilute WS with 1000 ml of fresh, deionised water then rinse vial several times. 
• Stability at 15-25◦C up to 60 days 
SAMPLE: 
• The Serum  
• Storage of specimens for 5 days at 2-8◦C and at -20◦C up to 30 days. 
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PROCEDURE: 
 
   
            1st STEP            WELL (µl) 
    A1…..D2 
CALIBRATORS 
       E2 
   SPECIMEN 
    CAL –A-F;  in duplicate           50          _ 
 SPECIMENS AND CONTROLS; 
(duplicate) 
            _         50 
  CONJUGATING AGENT           100         100 
 Gently  rock and cover MIC with strip 
Incubate  at 20….25◦C up to 60 min  
Wash -  3 times  
                WASH          300    300 
               2nd STEP  
              SUBSTRATE          100     100 
 No shaking MIC after  addition of 
SUB 
 
Incubated up to  15 min at 20…25◦C   
             STOP          50    50 
    Then  Mixed   
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 Absorbance measured at 450nm as early as possible or within 30min, after 
reaction termination takes place,  using a reference wavelength of  630- 
690nm. 
TEST VALIDATION: 
      Results are available if calibration of highest absorbance CAL- A ≥ 1.3. 
TEST CALCULATION: 
       Measured absorbance plotted against calibrator in a lin graph. Plotted 
measuring points result in a calibration curve, from which the concentration 
of analyte in the sample can be determined. 
 
REFERENCE VALUE: 
                             
                ADULT      PREGNANT 
                MEAN 1.4nanogram /ml       1.5 ng / ml 
   STANDARD DEVIATION      
(S.D) 
0.3nanogram /ml        0.37ng /ml 
EXPECTED RANGE (≥ 2 S.D ) 0.8-2.0nanogram 
/ml  
     0.8-2.2 ng/ ml 
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                                   ESTIMATION OF TSH 
 METHODOLOGY: 
     ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA METHOD) 
PRINCIPLE: 
     The ELISA which is used the principle of competitive binding between TSH in a 
test specimen and TSH –Peroxidase conjugated for the limited number of binding sites 
on the anti –TSH (Sheep) coated well. The amount of TSH –Peroxidase conjugate 
which is bound with the well and is inversely proportional to the TSH concentration in 
the specimen. 
   Incubated specimen and TSH –Peroxidase conjugation with unbound enzyme then 
conjugate is removed by washing procedure. Then TMB /Substrate solution is added 
and a blue color develops. This blue color intensity, which changes to yellow after 
stopping of   the reaction and is inversely proportional  to the TSH amount in the 
specimen. 
Calibrator’s   absorbance and specimen which is determined by using of ELISA 
microplate readers or automated ELISA systems (eg.HUMAN’S Huma - Reader or 
ELISYS line). Concentration of Specimen is extrapolated from a dose response curve 
generated by known antigen concentrations of serum calibrators .   
 KIT : 
MIC STRIPS  
8 - Well strips , coated by anti –TSH sheep) 
CALIBRATORS: ( 6cal  , 2 ml/ cal)  
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     TSH CONCNTRATION    Micro International Unit/mille litre 
       Calibrator  1     0 ( A) 
        Calibrator  2     0.5 (B) 
         Calibrator  3     3.0 (C) 
        Calibrator  4    6.0 (D) 
         Calibrator  5    15.0 (E) 
         Calibrator  6 30.0 (F) 
 
ENZYME – ANTIGEN CONJUGATE: (13 ml) 
      Red coloured anti-TSH (goat), labelled with HRP. 
WASH SOLUTION : (50 ml) 
    Concentrated for ca.1000ml – pH 6.25 ± 0.1 
    Tris buffered.  -  10mmol/l   
    NaCl                 - 8gm/l 
SUBSTRATE REAGENT :(13ml)  
          TMB –   1.2mmol/l 
          H2O2    -   ≤ 6.0 mmol/l 
STOP SOLUTION:  ( 15ml) 
    Sulphuric acid                                            -0.5 mol/l 
PRESERVATIVES: Total concentration < 0.1%. 
    Reagents stability are up to the stated expiry dates on the  labels ,when stored at 2-
8◦C. 
        MICROPLATE: 
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          An aluminium bag sealed with a desiccant. 
PREPARATION OF REAGENTS:  
• All reagents brought to the room temperature (15-25◦C ) before use. 
 
WORKING WASH SOLUTION: 
• Turbidity, which is faint and may appear in the concentrate, will dissolve 
completely on dilution. 
• WS 1 + 20 diluted with fresh, deionised water .eg 50 ml WS + 1000ml = 
1050ml. 
TET SAMPLE: 
• Serum sample 
• Storage of Specimens at 2-8◦C and at -20◦C, upto 5 days and 30 days 
respectively. 
PROCEDURE: 
Reagents and test sample must be at the room temperature before use. 
 
             1st STEP            WELL (µl) 
    A1…..D2 
CALIBRATORS 
       E2 
   SPECIMEN 
    CAL –A-F;  in duplicate           50          _ 
 SAMPLE AND CONTROLS;( 
duplicate) 
            _         50 
  CONJUGATE           100         100 
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Gently rock it and cover MIC with strip 
Incubation  at 20….25◦C up to 60 min 
Wash - 3 times  
                WASH          300    300 
                -2nd STEP  
              SUBSTRATE          100     100 
 No shaking MIC after addition of 
SUB 
 
Incubation  at 20…25◦C up to15 min   
             STOP          100    100 
   Then  mixed   
 
 
Absorbance measured at 450nm as early as possible or within 30minutes, 
after terminating of reaction, by using of a reference wavelength of  630- 
690nm. 
  TEST VALIDATION: 
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          CALIBRATOR        
RANGEOFACCEPTANCE(OD) 
                   A       < 0.05 
                   B      >2.0 × absorbance CAL(A) 
                   C     >3.0 × absorbance CAL(B) 
                   D   >1.4 ×  absorbance CAL(C) 
                   E     >1.9 × absorbance CAL(D) 
                   F    >1.5 × absorbance CAL(E) 
                  F      >1.2 
 
TEST CALCULATION: 
Measured the absorbance potted against calibrator in a Slin graph. Then 
plotted measuring points result in a calibration curve, from which the 
concentration of analyte in the sample which can be determined. 
 
REFERENCE VALUE: 
 NORMAL RANGE: 0.3 - 4.0 mIU/ml 
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                                 RESULTS AND STATISTICS: 
                  In this study 100 psoriatic patients (case) were enrolled over an eighteen 
months period, 30 non psoriatic patients, other skin disorders (controls). The majority 
of the patients were males (51%) and the mean age was (45.85 years) 
                 Table 1: Age distribution of the study population (n=130) 
Age group Cases  
N (%) 
Controls  
N (%) 
Total 
N (%) 
21- 30 years 15 (15) 5 (16.7) 20 (15.4) 
31 - 40 years 19 (19) 4 (13.3) 23 (17.7) 
41 – 50 years 28 (28) 9 (30) 37 (28.5) 
51 – 60 years 27 (27) 11 (36.7) 38 (29.2) 
>60 years 11 (11) 1 (3.3) 12 (9.2) 
Total 100 (100) 30 (100) 130 (100) 
 
Mean age: 45.85 years 
Standard deviation: 2.99 years 
 Minimum: 20 years 
Maximum: 75 years 
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Figure 1: Bar chart showing age distribution of the study population   
(n=130) 
 
 
Table 2: Comparison of age among cases and controls (n=130) “T” test 
Study Groups Average 
Age 
SD Mean 
difference 
p 
value 
95% confidence 
interval 
Cases 45.89 13.07 0.19 0.943 -5.10 to 5.48 
Controls 45.70 12.06 
 
 
Comments: There was a very minimal age mean difference between the cases and 
the controls and this difference was not statistically significant. Hence both cases and 
controls were comparable.  
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Table 3: Gender distribution of the study population (n=130) 
 
Gender Cases  
N (%) 
Controls  
N (%) 
Total 
N (%) 
Male 51 (51) 13 (43.3) 64 (49.2) 
Female 49 (49) 17 (56.7) 66 (50.8) 
Total 100 (100) 30 (100) 130 (100) 
 
Chi square value: 0.543   p value: 0.461 
Comments: Males and females were equally distributed in both cases and controls 
Figure 2: Bar chart showing gender distribution of the study population 
among cases and controls(n=130) 
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Table 4: Distribution of the Cases according to duration of Psoriasis 
(n=100) 
Duration of Psoriasis 
       (years) 
Frequency Percent 
1 to 5  22 22.0 
6 to 10  27 27.0 
11 to 15  6 6.0 
16 to 20 19 19.0 
21 to 25  11 11.0 
>25  15 15.0 
Total 100 100.0 
 
 
Mean disease duration: 16.06 years 
Standard deviation: 11.20 years 
Minimum: 1 year 
Maximum: 50 years 
Comments: About 50% of the cases had psoriasis for more than 10 years. 
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Figure 3: Bar chart showing Cases according to duration of Psoriasis 
(n=100) 
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Table 5 : Distribution of cases according to marital status (n= 100) 
 
 
Marital status Frequency Percent 
Unmarried 27 27.0 
Married – Non 
Consanguineous 
60 60.0 
Married – II degree 
Consanguineous 
3 3.0 
Married - III degree 
Consanguineous 
10 10.0 
Total 100 100.0 
 
Comments: About two-third of the cases had a non- consanguineous marriage while 
13% of cases had consanguineous marriage. 
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Figure 4: Pie chart showing Cases according to Marital status (n=100) 
 
 
Table 6: Distribution of the Cases according to Type of diet (n=100) 
Type of Diet Frequency Percent 
Non-vegetarian diet 83 83 
Vegetarian 17 17.0 
Total 100 100.0 
 
Comments: About 83% of cases were on non-vegetarian diet. 
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Figure 5: Doughnut chart showing Cases according to Type of diet (n=100) 
 
 
 
 
Table 7: Distribution of the Cases according to Type of residence (n=100) 
 
Type of residence Frequency Percent 
Urban 57 57.0 
Rural 43 43.0 
Total 100 100.0 
Comments: More than half of the subjects were urban areas and 43% rural areas 
subjects. 
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Figure 6: Pie chart showing Cases according to type of residence (n=100) 
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Table 8: Distribution of the Cases according to family history of psoriasis 
(n=100) 
 
Family history Frequency Percent 
Present 0 0 
Absent 100 100 
Total 100 100 
 
 
 
Table 9: Distribution of the Cases according to type of psoriasis (n=100) 
 
Type of Psoriasis Frequency Percent 
Erythrodermic 1 1.0 
Plaque 99 99.0 
Total 100 100.0 
 
 
Comments: Except a single case, all others had plaque type of psoriasis. 
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Table 10: Distribution of the Cases according to psoriatic arthritis/nail 
changes (n=100) 
 
Psoriatic arthritis/ 
Nail changes 
Frequency Percent 
Neither 72 72.0 
Only Nail changes 23 23.0 
Only Psoriatic arthritis 1 1.0 
Both present 4 4.0 
Total 100 100.0 
 
Comments: Nail changes were present in about one-fourth of the cases while 
arthritis was observed only in 1 case. Both the changes were seen together in 4 
patients. 
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Figure 7: Bar chart showing Cases according to psoriatic arthritis/nail 
changes (n=100) 
 
Table 11: Distribution of the Cases according to skin surface area 
involvement in psoriasis (n=100) 
 
BSA score Frequency Percent 
MILD-3% 50 50.0 
MODERATE-3-10% 41 41.0 
SEVERE >10% 9 9.0 
Total 100 100.0 
 
Comments: About half the cases had only mild involvement while 41% had 
moderate involvement of 3 to 10% of skin surface area. 
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Figure 8: Bar chart showing Cases according to skin surface area 
involvement in psoriasis (n=100) 
 
 
Table 12: Distribution of the Cases according to socio-economic status 
(Total number of population =100) 
SE status The Frequency % 
Low Socio Economic class 72 72 
Middle class 28 28 
Total 100 100.0 
 
Comments: About three-fourth of the cases belong to lower socio-economic status 
while others were from middle class. 
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Figure 9: Pie chart showing Cases according to socio-economic status 
(n=100) 
 
 
 
Table 13: Distribution of the Cases according to smoking status (n=100) 
Smoking status Frequency Percent 
Smoker 25 25 
Not a smoker 75 75 
Total 100 100.0 
 
Comments: About three-fourth of the cases were non-smokers while others were 
addicted to smoking. 
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Figure 10: Doughnut chart showing Cases according to smoking status 
(n=100) 
 
 
 
Table 14: Distribution of the Cases according to alcohol usage (n=100) 
 
Alcohol use Frequency Percent 
Present 17 17 
Absent 83 83 
Total 100 100.0 
 
Comments: 17% of cases reported use of alcohol in one form or the other. 
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Figure 11: Pie chart showing Cases according to alcohol usage (n=100) 
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Table 15: Distribution of the study population according to anthropometric 
parameters (n=130) 
 
 
Table 16: Distribution of the study population according to biochemical 
parameters (n=130) 
Statistic Height 
(cm) 
Weight 
(Kg) 
BMI Waist 
Circumf
erence 
(cm) 
Hip 
Circumf
erence 
(cm) 
Waist 
Hip 
Ratio 
Mean 158.05 59.48 22.770 77.35 79.25 .9759 
Std. 
Deviation 
4.934 8.277 6.4220 6.580 6.524 .01427 
Minimum 145 42 11.2 56 58 0.95 
Maximum 171 90 49.4 104 106 1.13 
Statistics FBG  
(milligram
/dl) 
TC (mg/dl) 
(milligram/dl 
Triglycerides 
(milligram/dl 
VLDL-c 
(milligram/
dl) 
LDL -c 
(milligram/
dl) 
HDL -c 
(milligra
m/dl) 
Mean 104.19 189.87 159.92 31.67 118.13 40.09 
Std. 
Deviation 
30.806 36.881 73.803 14.708 32.493 6.671 
Minimum 72 108 62 12 64 23 
Maximum 276 282 368 73 198 57 
85 
 
 
Table 17: The Metabolic Syndrome prevalence among psoriatic patients 
and controls (n=130) 
 
 
Parameter Group Frequency Percentage 
Waist circumference 
(in centimeter) 
Normal 
 
Elevated 
(>90 for males, >80 for 
females) 
 
111 
 
 
19 
 
85.4% 
 
 
14.6% 
 
Fasting Blood 
Glucose (mg/dl)* 
 
Normal (<100) 
 
Elevated (>100) 
 
91 
 
39 
 
70% 
 
30% 
Serum Triglyceride 
level (mg/dl)** 
Normal 
 
Elevated (>=150) 
73 
 
57 
56.2% 
 
43.8% 
Serum HDL level 
(mg/dl)*** 
Normal 
 
Reduced HDL 
(<40 for males,<50 for 
females) 
 
40 
 
 
90 
30.8% 
 
 
69.2% 
Blood pressure 
(mm Hg)**** 
Normal 
 
Elevated 
(SBP>+130 and/or 
DBP>=85) 
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33 
74.6% 
 
 
25.4% 
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Table 18: Distribution of Metabolic Syndrome components among psoriatic 
and non psoriatic subjects (n=130) 
 
 
Comments:  
1. Central obesity was almost equal in both cases and controls (14% versus 
16.percentage) ,  (p>0.05). 
2. Elevated Fasting Blood glucose was common in Cases (38%) than in controls 
(3.3%) and also elevated serum triglyceride level was more in cases (55%) than 
controls (6.7%) and this differences were  statistically significant (p<0.05). 
Components Group p value 
(Chi-square test) 
Cases 
N (%) 
Controls 
N (%) 
Waist 
circumference (in 
centimeter) 
 
Normal 
 
Elevated 
 
86 (86%) 
 
14 (14%) 
 
25 (83.3%) 
 
5 (16.7%) 
0.717 
Fasting Blood 
Glucose (mg/dl)* 
 
Normal 
 
Elevated 
 
62 (62%) 
 
38 (38%) 
 
29 (96.7%) 
 
1 (3.3%) 
<0.001 
Serum Triglyceride 
level (mg/dl)** 
 
Normal 
 
Elevated 
 
45 (45%) 
 
55 (55%) 
 
28 (93.3%) 
 
2 (6.7%) 
<0.001 
Serum HDL level 
(mg/dl)* 
 
Normal 
 
Reduced 
 
29 (29%) 
 
71 (71%) 
 
11 (36.7%) 
 
19 (63.3%) 
0.425 
**Blood pressure 
(mm Hg)**** 
 
Normal 
 
Elevated 
 
68 (68%) 
 
32 (32%) 
 
29 (96.7%) 
 
1 (3.3%) 
0.002 
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3. Reduced serum HDL level was more in cases (71%) than controls (63.3%) and 
it’s p value-   (p>0.05). 
4. Elevated blood pressure was common in Cases (32%) than in controls (3.3%) and 
these difference were statistically significant (p<0.05). 
5. In Cases, the components in descending order of prevalence are Reduced HDL > 
Raised level of Triglycerides > increased level of fasting glucose > Raised level 
of blood pressure > Central obesity. 
6. In controls, the components in descending order of prevalence are Reduced HDL 
> obesity > Elevated level of Triglycerides > Elevated blood pressure & Elevated 
fasting glucose. 
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Figure 12: Bar chart showing the Metabolic   Syndrome prevalence among 
study population and control group (n=130) 
 
Table 19:   Based on NCEP ATP III criteria MS components in both 
Psoriatic and non Psoriatic individuals:  (Total number  =130) 
 
 
Criteria Metabolic syndrome Frequency Percentage 
Modified NCEP 
Adult Treatment 
Panel III 
(ATP III) 
 
Present 
 
 
Absent 
 
 
38 
 
 
92 
 
 
29.2 % 
 
 
70.8 % 
 
 
Comments: Prevalence of metabolic syndrome was 29.2% among the study 
population 
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Table 20: Distribution of study population based on the individual MS 
components among cases and controls (n=130) 
Number of 
Components 
Frequency Percent 
No components 18 13.8 
1 43 33.1 
2 31 23.8 
3 21 16.2 
4 15 11.5 
5 (All 
components) 
2 1.5 
Total 130 100.0 
 
Comments:  
             1. About 14% of the study population were free from any MS component . 
2. About 86% had one or more components of metabolic syndrome, while 
1.5% were suffering from all 5 components of metabolic syndrome according 
to NCEP ATP III criteria. 
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Figure 13: Bar chart showed that the Metabolic Syndrome in both study 
and control groups (n=130) 
 
Table 21: Distribution of the metabolic syndrome among cases and controls 
(n=130) 
 
Metabolic syndrome Cases  
N (%) 
Controls  
N (%) 
Total 
N (%) 
Present 37 (37) 1 (3.3) 38 (29.2) 
Absent 63 (63) 29 (96.7) 92 (70.8) 
Total 100 (100) 30 (100) 130 (100) 
 
Chi square value: 0.543   p value: <0.001 
ODDS RATIO: 17.032  p value: 0.006 
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 Odds ratio: 2.22 to 130.25 
Comments:  
1. It’s prevalence was very high among cases (Thirty seven%) in comparison to 
controls (3.3%) and this difference was statistically significant. 
2. Cases had 17 times higher odds of having metabolic syndrome than controls and 
this risk was also statistically significant. 
Figure 14: Stacked Bar chart showing prevalence of Metabolic Syndrome 
among cases and controls (n=130) 
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Figure 15: Pie chart showing MS in study population (n=100) 
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Figure 16: Bar chart showing Number of Components of Metabolic 
Syndrome among study population (n=130) 
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Table 22: Comparison of age among cases with and without metabolic 
syndrome (n=100) 
                                                       The “t” test            
 
 
Metabolic 
Syndrome 
Average
Age 
SD Mean 
difference 
Value of 
p 
95% confidence 
interval 
Present (37) 52.41 10.76 10.34 <0.001* 5.35 to 15.32 
Absent (63) 42.06 12.86 
 
* Significant at 0.05 level 
 
Comments:  
The Metabolic Syndrome subjects had higher mean age of 52 years when compared to 
subjects without metabolic syndrome (42 years) and this mean difference was 
statistically significant. Hence, age of the patient which is an important factor in the 
occurrence of metabolic syndrome viz as age increases, risk of metabolic syndrome 
also increases. 
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Table 23: Comparison of duration of psoriasis among cases with and 
without metabolic syndrome (n=100) 
Student “T” test 
Metabolic 
Syndrome 
Mean 
duration of 
psoriasis 
Std. 
Deviation 
Mean 
difference 
p value 95% confidence 
interval 
Present (37) 20.49 12.74 7.025 0.002* 2.61 to 11.43 
Absent (63) 13.46 9.36 
 
* Significant at 0.05 level 
Comments:  
 The Metabolic Syndrome Subjects had higher duration of psoriasis in 
comparison to subjects without metabolic syndrome and this mean difference was 
statistically significant. Hence, duration of psoriasis was also very important factor in 
the occurrence of metabolic syndrome viz as duration of psoriasis increases, risk of 
metabolic syndrome also increases among patients. 
Table 24: Distribution of the metabolic syndrome among cases based on 
type of diet (n=100) 
Diet Metabolic 
syndrome  
NO Metabolic 
syndrome  
Total 
N (%) 
Non-Vegetarian 
N (%) 
33 (39.8) 50 (60.2) 83 (100) 
Vegetarian 
N (%) 
4 (23.5) 13 (76.5) 17 (100) 
Total 37 (37) 63 (63) 100 (100) 
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Chi square value: 1.594   p value: 0.207 
Comments: Metabolic syndrome was common among subjects taking non-
vegetarian diet (40%) than subjects taking vegetarian diet (23.5%) but this 
difference was not statistically significant. 
Table 25: Distribution of the metabolic syndrome among cases based on 
type of residence (n=100) 
Residence Metabolic 
syndrome  
NO Metabolic 
syndrome  
Total 
N (%) 
Urban 
N (%) 
21 (36.8) 36 (63.2) 57 (100) 
Rural 
N (%) 
16 (37.2) 27 (62.8) 43 (100) 
Total 37 (37) 63 (63) 100 (100) 
Chi square value: 0.001   p value: 0.970 
Comments: The occurrence of metabolic syndrome was almost same among all 
patients with psoriasis irrespective of their type of residence whether urban or 
rural. 
Table 26: Distribution of the metabolic syndrome among cases based on 
type of psoriasis (n=100) 
Psoriasis Metabolic 
syndrome  
NO Metabolic 
syndrome  
Total 
N (%) 
Erythrodermic 
N (%) 
0 (0) 1 (100) 1 (100) 
Plaque 
N (%) 
37 (37.4) 62 (62.6) 99 (100) 
Total 37 (37) 63 (63) 100 (100) 
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Comments: Metabolic syndrome and its association with type of psoriasis 
cannot be commented as only 1 patient had erythrodermic type of psoriasis and 
all the others had plaque type. 
 
Table 27: Distribution of the metabolic syndrome among cases based on 
severity of psoriasis according to BSA score (n=100) 
BSA score Metabolic 
syndrome 
NO Metabolic 
syndrome 
Total 
N (%) 
MILD-3% 18 (36) 32 (64) 50 (100) 
MODERATE-3-10% 15 (36.6) 26 (63.4) 41 (100) 
SEVERE >10% 4 (44.4) 5 (55.6) 9 (100) 
Total 37 (37) 63 (63) 100 (100) 
 
Chi square value: 0.238   p value: 0.888 
Comments: The occurrence of metabolic syndrome was almost same among all 
patients with psoriasis irrespective of severity of psoriasis according to BSA score. 
This indicates that the occurrence of metabolic syndrome is an ‘all or none’ 
phenomenon because of the underlying pathogenesis and is not associated with 
severity of disease. 
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Table 28: Distribution of the metabolic syndrome among cases with and 
without arthritis (n=100) 
Arthritis Metabolic 
syndrome  
NO Metabolic 
syndrome  
Total 
N (%) 
Absent 
N (%) 
35 (36.8) 60 (63.2) 95 (100) 
Present 
N (%) 
2 (40) 3 (60) 5 (100) 
Total 37 (37) 63 (63) 100 (100) 
 
Chi square value: 0.020   p value: 0.887 
Comments: The occurrence of metabolic syndrome was almost same among all 
patients with psoriasis irrespective of occurrence of arthritis. 
 
Table 29: Distribution of the metabolic syndrome among cases with and 
without nail changes (n=100) 
Nail changes Metabolic 
syndrome  
NO Metabolic 
syndrome  
Total 
N (%) 
Absent 
N (%) 
25 (34.2) 48 (65.8) 73 (100) 
Present 
N (%) 
12 (44.4) 15 (55.6) 27 (100) 
Total 37 (37) 63 (63) 100 (100) 
 
Chi square value: 0.879   p value: 0.348 
Comments: The occurrence of metabolic syndrome was almost same among all 
patients with psoriasis irrespective of occurrence of nail changes. 
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Table 30: Distribution of thyroid profile parameters between cases and 
controls (n = 130) 
 Group N Mean Mean 
difference 
Student “t” 
test 
p value 
FT3 
(pg/ml) 
 
Cases 100 2.117 0.0803 0.53 
Controls 30 2.037 
FT4 
(ng/dl) 
 
Cases 100 1.284 -0.0193 0.809 
Controls 30 1.303 
TSH (mIU/ml) Cases 100 3.580 1.303 0.001 
Controls 30 2.277 
 
Comments:  
1. Cases had higher mean TSH levels than controls (3.5 vs 2.2) and this mean 
difference was statistically significant 
2. Serum T3 and T4 values did not differ much between cases and controls and 
the minor difference was not statistically significant. 
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                                                         DISCUSSION  
Psoriasis   patients are at risk of developing MS, the proper mechanism of action 
involved is not known exactly. Gerald Reaven, an endocrinologist from Stanford 
University, first described the MS in 1988. MS and psoriasis share certain common 
immunological mechanisms. The abdominal (Intra) fat acts as an endocrine organ 
capable of secreting adipocytokines that accelerate inflammation, affect glucose 
metabolism and vascular endothelial biology 17. 
 Proinflammatory cytokines are found on plaques of psoriasis and these involved in 
the features of insulin resistance, dyslipidemia and hypertension. 
Leptin, another hormone secreted by the adipocytes, has a role in acute inflammation 
and chronic inflammation via the regulation of cytokine expression that modulates the 
type 1 and type 2 T-helper cells. Hyperleptinemia has been associated with the 
development of MS. Elevated leptin have also been observed in psoriasis. However, 
the exact effect in psoriasis is yet to be explored 64. 
Many studies have identified that psoriasis is associated with metabolic syndrome. 
Zindancy et al [25] after studying plaque type of 115 psoriatic patients and 140 healthy 
controls found the Insulin resistance syndrome in cases (53%) than controls (39%), (p 
value was <0.001). Gisondi et al 20, studied 338 plaque psoriatic patients as well as 
controls and they found MS which statistically significant in psoriatic subjects. 
(30.1%) controls (20.6%) , (p= 0.005) using (NCEP) ATP III criteria. 
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Sristi Lakshmi et al 29 south Indian study have shown that prevalence of metabolic 
syndrome in cases (32.5%) when compared to controls (30%) as per NCEP ATP III 
criteria, but the difference was not statistically significant. 
Our study observed that the prevalence of Metabolic Syndrome in cases out of 100 
psoriatic patients (37%), compared to controls out of skin disease patients other than 
psoriasis (3.3%), (p <0.001). 
According to Misra and Khurana 61, South Asian population is, in general inherently 
predisposed to an increased risk of metabolic syndrome and associated cardiovascular 
risk factor compared to Caucasians. 
MS in patients was associated with higher age in our study. Metabolic Syndrome 
subjects had higher mean age of (52 years)  when compared to subjects without 
metabolic syndrome (42 years) and , standard deviation (10.76), mean difference 
(10.34) this mean difference was statistically significant, (p < 0.01). Hence, age of the 
patient is very important factor in the occurrence of metabolic syndrome as age 
increases; risk of metabolic syndrome also increases. 
Gisondi et al 20. found that MS was common after 40 years of age. Zindancy et al 25 et 
al., found that MS was common in the age group of 40-50 years of age. 
Our study found that the occurrence of metabolic syndrome was almost same among 
all patients with psoriasis irrespective of severity of psoriasis according to BSA score. 
This indicates that the occurrence of metabolic syndrome is an ‘all or none’ 
phenomenon because of the underlying pathogenesis and is not associated with 
severity of disease. Zindancy et al 25 et al found that prevalence of MS was 
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independent of severity of psoriasis. Kim et al 62 found that MS was associated with 
severe forms of psoriasis (p=0.048). 
On analyzing the individual components of MS in psoriatic patients, Central obesity 
was almost equal in both cases and controls (14% versus sixteen. Seven%) but which 
value not  statistically significant (p value >0.05).Elevated Fasting Blood glucose was 
common in Cases (38%) than in controls (3.3%) , (p value < 0.001) and also elevated 
serum triglyceride level was more in cases (55%) than controls (6.7%) and  
differences were  statistically significant (p<0.05). 
Reduced serum HDL level was more in cases (71%) than controls (63.3%) and It’s 
difference  not significant statistically (p>0.05).Elevated blood pressure was common 
in Cases (32%) than in controls (3.3%) and  it  was statistically highly significant 
(p<0.05). 
  In Cases, the components in descending order of prevalence are Reduced HDL >   
Elevated level of Triglycerides > Raised FPG > Raised BP> Central obesity. In 
controls, the components in descending order of prevalence are Reduced HDL > 
Obesity > Elevated Triglycerides > Elevated blood pressure & Elevated fasting 
glucose. Increased blood sugar level was an important factor contributing to 
increased prevalence of MS in psoriatic patients. The possible explanation is 
that psoriasis and diabetes share common genetic loci. CDKLI gene has been 
associated with both psoriasis and type2 diabetes mellitus.  
About 14% of the study populations were free from any MS component by using 
NCEP Ault Treatment Panel III criteria. About 86% had one or more components of 
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metabolic syndrome, while 1.5% was suffering from all 5 Metabolic Syndrome 
components based on NCEP ATP III criteria. 
 Sristi Lakshmi et al 29 South Indian study found that statistically significant level of 
fasting blood sugar among those with MS ( P<0.001), but they could not found a 
significantly higher prevalence of other components of MS such as obesity, 
hypertension and dyslipidemia among psoriatic patients with MS. 
Several studies have demonstrated that higher lipid levels in psoriasis. Shapiro et al [26] 
found that psoriasis was associated hyperlipidemia.  
Several studies have found that IL-2 , IL-8 and Tumour Necrosis Factor-Alpha levels, 
correlate with psoriasis. These cytokines also play a role in the development of 
psoriasis 60. An increased level of these cytokines is a possible explanation of 
triglyceridemia in psoriasis. In our study duration of psoriasis higher when associated 
to MS than without MS and this mean difference was statistically significant. Mean 
duration of psoriasis (20.49), Std. Deviation (12.74), Mean difference (7.025), p value 
(0.002*).Hence, duration of psoriasis was also most important factor in the occurrence 
of metabolic syndrome as duration of psoriasis increases, risk of metabolic syndrome 
also increases among patients. 
Metabolic syndrome was common among subjects taking non-vegetarian diet (40%) 
than subjects taking vegetarian diet (23.5%) and this difference was not statistically 
significant ( p value: 0.207). 
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In this study the occurrence of metabolic syndrome was almost same among all 
patients with psoriasis irrespective of their type of residence whether urban or rural (p 
value: 0.970). 
In our study the occurrence of metabolic syndrome was almost same among all 
patients with psoriasis irrespective of occurrence of arthritis (p value: 0.887). The 
occurrence of metabolic syndrome was almost same among all patients with psoriasis 
irrespective of occurrence of nail changes (p value: 0.348). 
T3 and T4 thyroid hormones can play a role in psoriasis due to the mechanism of 
increasing the level of epidermal growth factor which may involved in the 
participation of keratinocyte proliferation. Many immunological mechanisms and 
biochemical processes, lead to enhanced action in the inflammation of the dermis and  
proliferation of epidermal cells . 
In our study level of FT3 (pg/ml) in cases Mean (2.117), in Controls Mean (2.037), 
Mean difference (0.0803), p value (0.53) FT4 (pg/ml) in cases Mean (1.284), in 
Controls Mean (1.303), Mean difference (-0.0193), p value (0.809). TSH (mIU/ml) in 
cases Mean (3.580), in Controls Mean (2.277), Mean difference (1.303), p value 
(0.001).  
Cases had higher mean TSH levels than controls (3.5 vs 2.2) and this mean difference 
was statistically significant. Serum T3 and T4 values did not differ much between 
cases and controls and the minor difference was not statistically significant. 
 
106 
 
 
 
 
 
 
 
         
 
 
 
                            
           CONCLUSION 
 
 
 
 
 
 
 
107 
 
 
                                 THE CONCLUSION OF STUDY 
       One the most common skin disorder in India is Psoriasis, both the 
epidemiological characteristics and its prevalence similar as in west.  results suggest 
that there is correlation between psoriasis and metabolic syndrome.  
Psoriasis may manifest as a multisystem disease not restricted to the skin and its 
appendages. The association of psoriasis with several comorbidities may occur due to 
various factors, such as the chronic inflammatory nature of the disease, genetic 
susceptibility, environmental factors and related to the patient’s quality of life and 
even adverse effects o drugs used for systemic therapy. 
Comorbidities that are associated with psoriasis greatly increase the morbidity and 
mortality of the disease. Many studies suggested that psoriasis may take a role as a 
risk factor for diseases such as ischemic heart disease. Therefore screening for 
metabolic syndrome which is essential to prevent the further complications. 
One of the important tissues for thyroid hormones is skin and this leads to rising of 
endothelial growth factor and therefore accelerates epidermal proliferation. Thyroid 
function test which can be useful in patients with relapsing psoriasis as well as in an 
uncontrolled Psoriasis. Thyroid hormones may play a role in the Psoriatic etiology so 
must be investigated  in wider clinical ,comprehensive and laboratory studies. 
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                                              CASE REPORT FORM 
 TITLE: “ A study of metabolic syndrome in psoriatic patients”- proforma: 
Name                         :                                                                           Date: 
Age/Sex                     :                                                                           OP/IP NO: 
Education                 : 
Occupation              : 
Place                        : 
 
Socioeconomic status :               Low/Middle/High 
 
Chief complaints   : 
 
 
Menstrual History: 
Cycle Duration                - 
Last Menstrual Periods   - 
 
Marital History: 
Duration             - 
Consanguinity    - 
Obstetric History: 
Number of children: 
 
Past History: 
DM/HT/Treatment/Drugs 
124 
 
 
Personal History: 
 
Family History: 
 
Concurrent illness: 
 
General examination: 
  Ht:                                       Wt:                                    BMI: 
  PR:                                       BP:                                   Thyroid: 
 Hip circumference:                                                       Waist circumference: 
 
Study specific physical examination : 
Skin: 
Morphology of the psoriatic lesion: 
 
                   Plaque  
                   Pustule  
                   Guttate  
                  Erythrodermic  
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Distribution of the lesion : 
 
     Scalp  
     Face  
     Trunk  
     Extremities  
     Palms  
     Soles  
     Flexural  
BSA Score ( Body Surface Area Score ) 
 
  Mild    3% 
  Moderate    3-10% 
  Severe   >10% 
 
Nail Changes                  : (+)/ (-) 
Psoriatic Arthritis         : (+)/ (-) 
 
Systemic examination     : CVS                : 
                                              RS                  : 
                                             ABDOMEN    : 
                                             CNS                 : 
Investigations done  : 
Hb% 
TC 
DC 
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Platelets 
Blood urea 
Plasma glucose 
Serum creatinine 
Liver function test: 
S. Protein A/G : 
S. Bilirubin : 
GGT : 
AST : 
ALT : 
ALP : 
 
Special investigations to be done : 
Fasting blood glucose: 
 
Lipid profile: 
 
               DATE                 VALUES 
 S. T. CHOLESTEROL  
S. TGL  
S. VLDL  
S.  LDL  
S. HDL  
Thyroid profile : 
              DATE                     VALUES 
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               FT3  
               FT4  
               TSH  
Skin biopsy: 
Investigator comment: 
 
Signature of the principle investigator: 
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                                                             Consent Form 
 
 You are requested to participate in a study conducted in the Department of Biochemistry, Chennai 
Medical College Hospital & Research Centre, Irungalur, Trichy, Tamilnadu, titled (A study of Metabolic 
Syndrome in Psoriatic patients) “Estimation of blood gluose, serum lipid profile, .serum thyroid profile.Your 
participation in the study is voluntary. 
 
• There will be no cost for participating in the study 
• Your participation is not a compulsion 
• You have the right to withdraw from the study at any time. 
 
Nature of Study: 
• If any abnormalities are identified, you will be informed for further consultation. 
• The results of this study will be kept confidential. 
 
We believe that the results of this study will be beneficial for advancements in medicine & Science.  We assure 
you that we will not use these result for any other purpose. 
 
Consent 
 
 I Mr. / Mrs. / Ms. _________________________________________________ residing at 
____________________________________________________________ 
_________________________________________________________________ on this day 
___________________ after having read the consent form carrying information for the above mentioned study 
and I hereby give my consent to take 5 ml of my blood sample for the purpose of doing, “Estimation of blood 
gluose, serum lipid profile, .serum thyroid profile. 
I was explained about the procedure in detail and give my consent for participating in the study and for using the 
results for Medical & Scientific purposes. 
 
 
Signature of the participant  Signature of the Investigator 
 
Chennai Medical College Hospital & Research Centre 
Irungalur,Trichy – 621 105. 
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